434 related articles for article (PubMed ID: 19112807)
1. Cutaneous drug eruptions induced by sorafenib: a case series.
Maddox JS; Kung EF; Petronic-Rosic V; Sethi A
J Drugs Dermatol; 2008 Sep; 7(9):891-3. PubMed ID: 19112807
[TBL] [Abstract][Full Text] [Related]
2. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
Autier J; Escudier B; Wechsler J; Spatz A; Robert C
Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma.
Diamantis ML; Chon SY
J Drugs Dermatol; 2010 Feb; 9(2):169-71. PubMed ID: 20214183
[TBL] [Abstract][Full Text] [Related]
4. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor.
Lacouture ME; Desai A; Soltani K; Petronic-Rosic V; Laumann AE; Ratain MJ; Stadler WM
Clin Exp Dermatol; 2006 Nov; 31(6):783-5. PubMed ID: 16824050
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors.
Minami H; Kawada K; Ebi H; Kitagawa K; Kim YI; Araki K; Mukai H; Tahara M; Nakajima H; Nakajima K
Cancer Sci; 2008 Jul; 99(7):1492-8. PubMed ID: 18477034
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
Adnane L; Trail PA; Taylor I; Wilhelm SM
Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
[TBL] [Abstract][Full Text] [Related]
7. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
Yang CH; Lin WC; Chuang CK; Chang YC; Pang ST; Lin YC; Kuo TT; Hsieh JJ; Chang JW
Br J Dermatol; 2008 Mar; 158(3):592-6. PubMed ID: 18070211
[TBL] [Abstract][Full Text] [Related]
8. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
Strumberg D; Clark JW; Awada A; Moore MJ; Richly H; Hendlisz A; Hirte HW; Eder JP; Lenz HJ; Schwartz B
Oncologist; 2007 Apr; 12(4):426-37. PubMed ID: 17470685
[TBL] [Abstract][Full Text] [Related]
9. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
Akaza H; Tsukamoto T; Murai M; Nakajima K; Naito S
Jpn J Clin Oncol; 2007 Oct; 37(10):755-62. PubMed ID: 17951335
[TBL] [Abstract][Full Text] [Related]
10. Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib.
Beldner M; Jacobson M; Burges GE; Dewaay D; Maize JC; Chaudhary UB
Oncologist; 2007 Oct; 12(10):1178-82. PubMed ID: 17962611
[TBL] [Abstract][Full Text] [Related]
11. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
12. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib: a promising new targeted therapy for renal cell carcinoma.
Wood LS; Manchen B
Clin J Oncol Nurs; 2007 Oct; 11(5):649-56. PubMed ID: 17962173
[TBL] [Abstract][Full Text] [Related]
14. Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors.
Smith KJ; Haley H; Hamza S; Skelton HG
Dermatol Surg; 2009 Nov; 35(11):1766-70. PubMed ID: 19660024
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib: atypical cutaneous side effects.
Richetta AG; Maiani E; Carboni V; Carlomagno V; Cimillo M; Mattozzi C; Calvieri S
Eur J Dermatol; 2007; 17(6):549-50. PubMed ID: 17951148
[No Abstract] [Full Text] [Related]
16. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
[TBL] [Abstract][Full Text] [Related]
17. Chloracne-like drug eruption associated with sorafenib.
Pickert A; Hughes M; Wells M
J Drugs Dermatol; 2011 Nov; 10(11):1331-4. PubMed ID: 22052319
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib-induced palmoplantar hyperkeratosis.
Lountzis NI; Maroon MS
J Drugs Dermatol; 2008 Jun; 7(6):588-9. PubMed ID: 18561593
[TBL] [Abstract][Full Text] [Related]
19. Severe sorafenib-induced hand-foot skin reaction.
Cuesta L; Betlloch I; Toledo F; Latorre N; Monteagudo A
Dermatol Online J; 2011 May; 17(5):14. PubMed ID: 21635836
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
